Pharmacological therapy for proliferative vitreoretinopathy.
We developed an animal model in the rabbit eye with intravitreally injected heterotransplanted bovine retinal pigment epithelial cells to test a pharmacological agent which would reduce extracellular matrix formation. Results with 20 and 60 micrograms of cis-hydroxyproline showed a 48% decrease in the rate of traction retinal detachments.